454 related articles for article (PubMed ID: 9044834)
21. Expression of CDK inhibitor genes in immortalized and carcinoma derived breast cell lines.
Zhou JN; Linder S
Anticancer Res; 1996; 16(4A):1931-5. PubMed ID: 8712723
[TBL] [Abstract][Full Text] [Related]
22. The biphasic induction of p21 and p27 in breast cancer cells by modulators of cAMP is posttranscriptionally regulated and independent of the PKA pathway.
Rao S; Gray-Bablin J; Herliczek TW; Keyomarsi K
Exp Cell Res; 1999 Oct; 252(1):211-23. PubMed ID: 10502413
[TBL] [Abstract][Full Text] [Related]
23. Accumulation of the cyclin-dependent kinase inhibitor p27/Kip1 and the timing of oligodendrocyte differentiation.
Durand B; Gao FB; Raff M
EMBO J; 1997 Jan; 16(2):306-17. PubMed ID: 9029151
[TBL] [Abstract][Full Text] [Related]
24. Molecular analysis of the cyclin-dependent kinase inhibitor gene p27/Kip1 in human malignancies.
Kawamata N; Morosetti R; Miller CW; Park D; Spirin KS; Nakamaki T; Takeuchi S; Hatta Y; Simpson J; Wilcyznski S
Cancer Res; 1995 Jun; 55(11):2266-9. PubMed ID: 7757974
[TBL] [Abstract][Full Text] [Related]
25. Lack of imprinting of three human cyclin-dependent kinase inhibitor genes.
Cost GJ; Thompson JS; Reichard BA; Lee JY; Feinberg AP
Cancer Res; 1997 Mar; 57(5):926-9. PubMed ID: 9041196
[TBL] [Abstract][Full Text] [Related]
26. Transforming growth factor-beta1 up-regulates p15, p21 and p27 and blocks cell cycling in G1 in human prostate epithelium.
Robson CN; Gnanapragasam V; Byrne RL; Collins AT; Neal DE
J Endocrinol; 1999 Feb; 160(2):257-66. PubMed ID: 9924195
[TBL] [Abstract][Full Text] [Related]
27. The prognostic significance of altered cyclin-dependent kinase inhibitors in human cancer.
Tsihlias J; Kapusta L; Slingerland J
Annu Rev Med; 1999; 50():401-23. PubMed ID: 10073286
[TBL] [Abstract][Full Text] [Related]
28. Lovastatin inhibits proliferation of anaplastic thyroid cancer cells through up-regulation of p27 by interfering with the Rho/ROCK-mediated pathway.
Zhong WB; Hsu SP; Ho PY; Liang YC; Chang TC; Lee WS
Biochem Pharmacol; 2011 Dec; 82(11):1663-72. PubMed ID: 21907187
[TBL] [Abstract][Full Text] [Related]
29. Frequent loss of heterozygosity on chromosome 9, and low incidence of mutations of cyclin-dependent kinase inhibitors p15 (MTS2) and p16 (MTS1) genes in gliomas.
Li YJ; Hoang-Xuan K; Delattre JY; Poisson M; Thomas G; Hamelin R
Oncogene; 1995 Aug; 11(3):597-600. PubMed ID: 7630644
[TBL] [Abstract][Full Text] [Related]
30. Genetic status and expression of the cyclin-dependent kinase inhibitors in human gastric carcinoma cell lines.
Akama Y; Yasui W; Kuniyasu H; Yokozaki H; Akagi M; Tahara H; Ishikawa T; Tahara E
Jpn J Cancer Res; 1996 Aug; 87(8):824-30. PubMed ID: 8797888
[TBL] [Abstract][Full Text] [Related]
31. 3,5,3',4',5'-pentamethoxystilbene (MR-5), a synthetically methoxylated analogue of resveratrol, inhibits growth and induces G1 cell cycle arrest of human breast carcinoma MCF-7 cells.
Pan MH; Lin CL; Tsai JH; Ho CT; Chen WJ
J Agric Food Chem; 2010 Jan; 58(1):226-34. PubMed ID: 19916542
[TBL] [Abstract][Full Text] [Related]
32. Redistribution of the CDK inhibitor p27 between different cyclin.CDK complexes in the mouse fibroblast cell cycle and in cells arrested with lovastatin or ultraviolet irradiation.
Poon RY; Toyoshima H; Hunter T
Mol Biol Cell; 1995 Sep; 6(9):1197-213. PubMed ID: 8534916
[TBL] [Abstract][Full Text] [Related]
33. TReP-132 controls cell proliferation by regulating the expression of the cyclin-dependent kinase inhibitors p21WAF1/Cip1 and p27Kip1.
Gizard F; Robillard R; Barbier O; Quatannens B; Faucompré A; Révillion F; Peyrat JP; Staels B; Hum DW
Mol Cell Biol; 2005 Jun; 25(11):4335-48. PubMed ID: 15899840
[TBL] [Abstract][Full Text] [Related]
34. Role of cyclin-dependent kinases and their inhibitors in cellular differentiation and development.
Chellappan SP; Giordano A; Fisher PB
Curr Top Microbiol Immunol; 1998; 227():57-103. PubMed ID: 9479826
[No Abstract] [Full Text] [Related]
35. Protection against chemotherapy-induced cytotoxicity by cyclin-dependent kinase inhibitors (CKI) in CKI-responsive cells compared with CKI-unresponsive cells.
Schmidt M; Fan Z
Oncogene; 2001 Sep; 20(43):6164-71. PubMed ID: 11593424
[TBL] [Abstract][Full Text] [Related]
36. Regulation of cyclin dependent kinase inhibitor proteins during neonatal cerebella development.
Watanabe G; Pena P; Shambaugh GE; Haines GK; Pestell RG
Brain Res Dev Brain Res; 1998 Jun; 108(1-2):77-87. PubMed ID: 9693786
[TBL] [Abstract][Full Text] [Related]
37. Evidence for different modes of action of cyclin-dependent kinase inhibitors: p15 and p16 bind to kinases, p21 and p27 bind to cyclins.
Hall M; Bates S; Peters G
Oncogene; 1995 Oct; 11(8):1581-8. PubMed ID: 7478582
[TBL] [Abstract][Full Text] [Related]
38. Expression of the p16 and p15 cyclin-dependent kinase inhibitors in lymphocyte activation and neuronal differentiation.
Lois AF; Cooper LT; Geng Y; Nobori T; Carson D
Cancer Res; 1995 Sep; 55(18):4010-3. PubMed ID: 7664273
[TBL] [Abstract][Full Text] [Related]
39. Decreased proliferation and cell cycle arrest in neoplastic rat pituitary cells is associated with transforming growth factor-beta1-induced expression of p15/INK4B.
Frost SJ; Simpson DJ; Farrell WE
Mol Cell Endocrinol; 2001 May; 176(1-2):29-37. PubMed ID: 11369440
[TBL] [Abstract][Full Text] [Related]
40. Involvement of p21(WAF1/Cip1) and p27(Kip1) in intestinal epithelial cell differentiation.
Tian JQ; Quaroni A
Am J Physiol; 1999 Jun; 276(6):C1245-58. PubMed ID: 10362586
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
